Search Results for: Semma

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc

/ / 1 Comment
Katarina-Le-Blanc

The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical […]

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »

New biotech Semma Therapeutics stem cell diabetes arena

/ / 2 Comments
Semma_05-4065

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston

New biotech Semma Therapeutics stem cell diabetes arena Read More »

Poll on stem cell & regenerative medicine good news of 2024

/ / 1 Comment
stem cell good news, good news

What are the most significant stem cell and regenerative medicine good news stories of 2024? Since it has been an eventful year, there are many possibilities. Please see our poll at the bottom of this post and weigh in on what you think is the most important encouraging news. If you don’t see your choice

Poll on stem cell & regenerative medicine good news of 2024 Read More »

Weekly reads: stem cell patches, helicase editing, hearing loss, Astellas, Dr. No

/ / Leave a Comment

New research on stem cell patches is exciting. However, more broadly, “stem cell patches” can mean very different things. What I’m talking about here are the types of patches that can repair holes or other problems with tissues. This is a powerful regenerative approach. In contrast, I’m not a fan of the type of stem cell

Weekly reads: stem cell patches, helicase editing, hearing loss, Astellas, Dr. No Read More »

Weekly reads: More good news on stem cells for diabetes, Panda stem cells, pricey longevity club

/ / 1 Comment
stem cell therapy for diabetes

People often ask me what is the most promising new cell therapy and while it is difficult to choose just one, I often highlight the promise of stem cells for diabetes. Here in the U.S., early data from diabetes clinical trials by Vertex look encouraging. Other teams worldwide are also working in this space and

Weekly reads: More good news on stem cells for diabetes, Panda stem cells, pricey longevity club Read More »

Weekly reads: Vertex stem cells for diabetes, storing iPS cells on the Moon, science hype award nominees

/ / Leave a Comment
Felicia Pagliuca, stem cells for diabetes

How is research looking on stem cells for diabetes? I’m feeling more encouraged about the clinical research in that area. Before we jump into that let’s talk about two other things.  The big news of the week was the felony plea deal by Liveyon’s John Kosolcharoen to charges related to marketing an unapproved cell therapy

Weekly reads: Vertex stem cells for diabetes, storing iPS cells on the Moon, science hype award nominees Read More »

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

/ / 5 Comments
CRISPR Therapeutics

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron

/ / 5 Comments
Vericel, Cell Therapy Companies

Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes

/ / 2 Comments
Doug Melton, Vertex, ViaCyte

When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »